A method for concentrating lipid peptide DNA and siRNA nanocomplexes that retains their structure and transfection efficiency

International Journal of Nanomedicine

Volumn 10, Issue , 2015, Pages 2673-2683

  Tagalakis, Aristides D ^a   Castellaro, Sara ^a,b   Zhou, Haiyan ^a   Bienemann, Alison ^c   Munye, Mustafa M ^a   McCarthy, David ^d   White, Edward A ^c   Hart, Stephen L ^a  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

^b UNIVERSITY OF GENOA   (Italy)

^c UNIVERSITY OF BRISTOL   (United Kingdom)

^d UNIVERSITY OF LONDON   (United Kingdom)

Author keywords

Anionic liposome; Concentration; DNA; Nanoparticles; siRNA; Targeted gene delivery

Indexed keywords

BETA SECRETASE; DNA; LIPID PEPTIDE DNA; LIPID PEPTIDE RNA; POLYMER; SMALL INTERFERING RNA; UNCLASSIFIED DRUG; LIPID; NANOPARTICLE; PEPTIDE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BACE1 GENE; BIOPHYSICS; CELL CULTURE; COMPLEX FORMATION; CONCENTRATION RESPONSE; CONTROLLED STUDY; CORPUS STRIATUM; DNA TRANSFECTION; DRUG FORMULATION; DRUG MIXTURE; DRUG STRUCTURE; FEMALE; GENE DELIVERY SYSTEM; GENE SILENCING; IN VITRO GENE TRANSFER; IN VIVO GENE TRANSFER; MOUSE; NANOPHARMACEUTICS; NONHUMAN; RAT; ROOM TEMPERATURE; THERMODYNAMICS; ANIMAL; CHEMISTRY; GENETIC TRANSFECTION; HUMAN; ISOLATION AND PURIFICATION; PROCEDURES; TUMOR CELL LINE;

ANIMALS; CELL LINE, TUMOR; DNA; HUMANS; LIPIDS; MICE; NANOPARTICLES; PEPTIDES; RNA, SMALL INTERFERING; TRANSFECTION;

EID: 84928113980     PISSN: 11769114     EISSN: 11782013     Source Type: Journal    
DOI: 10.2147/IJN.S78935     Document Type: Article

References (41)

1. Couvreur P, Barratt G, Fattal E, Legrand P, Vauthier C. Nanocapsule technology: a review. Crit Rev Ther Drug Carrier Syst. 2002;19(2):99-134.
2. Glover DJ, Lipps HJ, Jans DA. Towards safe, non-viral therapeutic gene expression in humans. Nat Rev Genet. 2005;6(4):299-310.
3. Love KT, Mahon KP, Levins CG, et al. Lipid-like materials for low-dose, in vivo gene silencing. Proc Natl Acad Sci U S A. 2010;107(5):1864-1869.
4. Schmidt-Wolf GD, Schmidt-Wolf IG. Non-viral and hybrid vectors in human gene therapy: an update. Trends Mol Med. 2003;9(2):67-72.
5. Semple SC, Akinc A, Chen J, et al. Rational design of cationic lipids for siRNA delivery. Nat Biotechnol. 2010;28(2):172-176.
6. Sheridan C. Gene therapy finds its niche. Nat Biotechnol. 2011;29(2):121-128.
7. Tagalakis AD, Diakonov IA, Graham IR, et al. Apolipoprotein E delivery by peritoneal implantation of encapsulated recombinant cells improves the hyperlipidaemic profile in apoE-deficient mice. Biochim Biophys Acta. 2005;1686(3):190-199.
8. Yin H, Kanasty RL, Eltoukhy AA, Vegas AJ, Dorkin JR, Anderson DG. Non-viral vectors for gene-based therapy. Nat Rev Genet. 2014;15(8):541-555.
9. Zhang Y, Satterlee A, Huang L. In vivo gene delivery by nonviral vectors: overcoming hurdles? Mol Ther. 2012;20(7):1298-1304.
10. Anchordoquy TJ, Armstrong TK, Molina MD. Low molecular weight dextrans stabilize nonviral vectors during lyophilization at low osmolalities: concentrating suspensions by rehydration to reduced volumes. J Pharm Sci. 2005;94(6):1226-1236.
11. Grosse SM, Tagalakis AD, Mustapa MF, et al. Tumor-specific gene transfer with receptor-mediated nanocomplexes modified by polyethylene glycol shielding and endosomally cleavable lipid and peptide linkers. FASEB J. 2010;24(7):2301-2313.
12. Manunta MD, McAnulty RJ, Tagalakis AD, et al. Nebulisation of receptor-targeted nanocomplexes for gene delivery to the airway epithelium. PLoS One. 2011;6(10):e26768.
13. Tagalakis AD, Grosse SM, Meng QH, et al. Integrin-targeted nanocomplexes for tumour specific delivery and therapy by systemic administration. Biomaterials. 2011;32(5):1370-1376.
14. Tagalakis AD, McAnulty RJ, Devaney J, et al. A receptor-targeted nanocomplex vector system optimized for respiratory gene transfer. Mol Ther. 2008;16(5):907-915.
15. Kenny GD, Bienemann AS, Tagalakis AD, et al. Multifunctional receptor-targeted nanocomplexes for the delivery of therapeutic nucleic acids to the brain. Biomaterials. 2013;34(36):9190-9200.
16. Tagalakis AD, Kenny GD, Bienemann AS, et al. PEGylation improves the receptor-mediated transfection efficiency of peptide-targeted, self-assembling, anionic nanocomplexes. J Control Release. 2014;174:177-187.
17. Du Z, Munye MM, Tagalakis AD, Manunta MD, Hart SL. The role of the helper lipid on the DNA transfection efficiency of lipopolyplex formulations. Sci Rep. 2014;4:7107.
18. Meng QH, Irvine S, Tagalakis AD, McAnulty RJ, McEwan JR, Hart SL. Inhibition of neointimal hyperplasia in a rabbit vein graft model following non-viral transfection with human iNOS cDNA. Gene Ther. 2013;20(10):979-986.
19. Tagalakis AD, He L, Saraiva L, Gustafsson KT, Hart SL. Receptor-targeted liposome-peptide nanocomplexes for siRNA delivery. Biomaterials. 2011;32(26):6302-6315.
20. Tagalakis AD, Saraiva L, McCarthy D, Gustafsson KT, Hart SL. Comparison of nanocomplexes with branched and linear peptides for siRNA delivery. Biomacromolecules. 2013;14(3):761-770.
21. Tagalakis AD, Lee DHD, Bienemann AS, et al. Multifunctional, self-assembling anionic peptide-lipid nanocomplexes for targeted siRNA delivery. Biomaterials. 2014;35(29):8406-8415.
22. Kenny GD, Villegas-Llerena C, Tagalakis AD, et al. Multifunctional receptor-targeted nanocomplexes for magnetic resonance imaging and transfection of tumours. Biomaterials. 2012;33(29):7241-7250.
23. Couvreur P, Vauthier C. Nanotechnology: intelligent design to treat complex disease. Pharm Res. 2006;23(7):1417-1450.
24. Acebal CC, Simonet BM, Valcárcel M. Nanoparticles and continuous-flow systems combine synergistically or preconcentration. TrAC Trends in Analytical Chemistry. 2013;43:109-120.
25. Belliveau NM, Huft J, Lin PJ, et al. Microfluidic synthesis of highly potent limit-size lipid nanoparticles for in vivo delivery of siRNA. Mol Ther Nucleic Acids. 2012;1:e37.
26. Davies LA, Nunez-Alonso GA, Hebel HL, et al. A novel mixing device for the reproducible generation of nonviral gene therapy formulations. Biotechniques. 2010;49(3):666-668.
27. Valencia PM, Farokhzad OC, Karnik R, Langer R. Microfluidic technologies for accelerating the clinical translation of nanoparticles. Nat Nanotechnol. 2012;7(10):623-629.
28. Vauthier C, Cabane B, Labarre D. How to concentrate nanoparticles and avoid aggregation? Eur J Pharm Biopharm. 2008;69(2):466-475.
29. Zelphati O, Nguyen C, Ferrari M, Felgner J, Tsai Y, Felgner PL. Stable and monodisperse lipoplex formulations for gene delivery. Gene Ther. 1998;5(9):1272-1282.
30. Kumar P, Wu H, McBride JL, et al. Transvascular delivery of small interfering RNA to the central nervous system. Nature. 2007;448(7149):39-43.
31. Cole SL, Vassar R. The role of amyloid precursor protein processing by BACE1, the beta-secretase, in Alzheimer disease pathophysiology. J Biol Chem. 2008;283(44):29621-29625.
32. Golde TE, Dickson D, Hutton M. Filling the gaps in the abeta cascade hypothesis of Alzheimer's disease. Curr Alzheimer Res. 2006;3(5):421-430.
33. Alvarez-Erviti L, Seow Y, Yin H, Betts C, Lakhal S, Wood MJ. Delivery of siRNA to the mouse brain by systemic injection of targeted exosomes. Nat Biotechnol. 2011;29(4):341-345.
34. Kim SS, Ye C, Kumar P, et al. Targeted delivery of siRNA to macrophages for anti-inflammatory treatment. Mol Ther. 2010;18(5):993-1001.
35. Zadran S, Akopian G, Zadran H, Walsh J, Baudry M. RVG-mediated calpain2 gene silencing in the brain impairs learning and memory. Neuromolecular Med. 2013;15(1):74-81.
36. Gao Y, Wang ZY, Zhang J, et al. RVG-peptide-linked trimethylated chitosan for delivery of siRNA to the brain. Biomacromolecules. 2014;15(3):1010-1018.
37. Kim JY, Choi WI, Kim YH, Tae G. Brain-targeted delivery of protein using chitosan- and RVG peptide-conjugated, pluronic-based nano-carrier. Biomaterials. 2013;34(4):1170-1178.
38. Bobo RH, Laske DW, Akbasak A, Morrison PF, Dedrick RL, Oldfield EH. Convection-enhanced delivery of macromolecules in the brain. Proc Natl Acad Sci U S A. 1994;91(6):2076-2080.
39. Gill SS, Patel NK, Hotton GR, et al. Direct brain infusion of glial cell line-derived neurotrophic factor in Parkinson disease. Nat Med. 2003;9(5):589-595.
40. Rohn S, Suttkus A, Arendt T, Ueberham U. RVG peptide as transfection reagent for specific cdk4 gene silencing in vitro and in vivo. J Drug Target. 2012;20(4):381-388.
41. White E, Bienemann A, Megraw L, Bunnun C, Gill S. Evaluation and optimization of the administration of a selectively replicating herpes simplex viral vector to the brain by convection-enhanced delivery. Cancer Gene Ther. 2011;18(5):358-369.